|
| Status |
Public on Mar 04, 2013 |
| Title |
E176_30_Placebo_2_A |
| Sample type |
RNA |
| |
|
| Source name |
PBMC
|
| Organism |
Homo sapiens |
| Characteristics |
sample: E176_30_Placebo_2
treatment: Placebo
weeks of treatment: 2
subject: E176_30
|
| Treatment protocol |
Human PBMCs were isolated by stratifying of whole blood on Ficoll-Paque PREMIUM (GE Healthcare; Pscataway, NJ). Subjects were randomized in a 1:1 fashion to receive either metreleptin or placebo, for a period of 36 weeks in the form of a self-administered daily subcutaneous injection.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was isolated from PBMCs using the manufacturer’s protocol for Trizol Reagent (Invitrogen, Grand Island, NY) and further purified using RNAeasy spin columns (Qiagen, Valencia, CA). RNA concentration and purity were determined from 260nm/280 nm absorbances. RNA integrity was determined using the Agilent 2100 BioChip (Agilent Technologies, Palo Alto, CA).
|
| Label |
biotin
|
| Label protocol |
biotin, according to manufacturer's recommendations
|
| |
|
| Hybridization protocol |
cRNA, according to manufacturer's recommendations
|
| Scan protocol |
according to manufacturer's recommendations
|
| Data processing |
RMA; RMA preprocessed log2 expression values
|
| |
|
| Submission date |
Apr 02, 2012 |
| Last update date |
Mar 04, 2013 |
| Contact name |
Dario Greco |
| E-mail(s) |
dario.greco@tuni.fi
|
| Organization name |
Tampere University
|
| Department |
Faculty of Medicine and Health Technology
|
| Lab |
Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE)
|
| Street address |
Arvo ylpön Katu 34
|
| City |
Tampere |
| ZIP/Postal code |
33520 |
| Country |
Finland |
| |
|
| Platform ID |
GPL15395 |
| Series (1) |
| GSE36990 |
Gene expression profile of PBMCs in response to metreleptin treatment at different time points. |
|
